NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases

[1]  A. Ohtsu,et al.  Therapeutic landscape and future direction of metastatic colorectal cancer , 2023, Nature Reviews Gastroenterology & Hepatology.

[2]  E. Oki,et al.  Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer , 2023, Nature Medicine.

[3]  A. Ohtsu,et al.  Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data. , 2022, Clinical colorectal cancer.

[4]  S. Truant,et al.  Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study , 2022, World Journal of Surgical Oncology.

[5]  S. Nomura,et al.  Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial , 2021, Nature Medicine.

[6]  S. Nomura,et al.  BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases , 2021, Cancer medicine.

[7]  E. Van Cutsem,et al.  O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer , 2021, Annals of Oncology.

[8]  E. Oki,et al.  CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer , 2021, Cancer science.

[9]  J. Desai,et al.  Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Takahashi,et al.  Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan , 2020, Annals of Surgical Oncology.

[11]  J. Vauthey,et al.  An Odyssey into the Land of Deleterious Rare Mutations in Colorectal Liver Metastases , 2020, Annals of Surgical Oncology.

[12]  T. Yoshino,et al.  ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into “Precision Oncosurgery” in Colorectal Liver Metastases , 2020, Annals of Surgical Oncology.

[13]  Vinod Sharma,et al.  Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2020, The New England journal of medicine.

[14]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer , 2019, International Journal of Clinical Oncology.

[15]  P. Lønning,et al.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer , 2018, JAMA surgery.

[16]  Jeffrey E. Lee,et al.  Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. , 2018, The Lancet. Oncology.

[17]  A. Kiani,et al.  Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. , 2017, European journal of cancer.

[18]  M. Kendrick,et al.  Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. , 2017, The oncologist.

[19]  V. Heinemann,et al.  Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Rugge,et al.  BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.

[21]  R. Hall,et al.  BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[22]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[23]  C. Bokemeyer,et al.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.

[24]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[25]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[26]  M. Gönen,et al.  Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. , 2018, Annals of surgery.

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[28]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..